A new eye drop has been approved by the Food and Drug Administration as a treatment for age-related near-sightedness. According to the researchers, these eye drop solutions will have better vision throughout the day and might rule out the erst to require reading glasses.
The formulation of Vuity contains a drug known as pilocarpine. In order to facilitate rapid adaptation to tear film pH, researchers developed technology to allow eye drops to rapidly rebalance. By taking advantage of our eyes’ ability to shrink pupil size, we are able to improve near and intermediate vision while retaining distance vision.
750 subjects with presbyopia, aged 40 to 55, participated in two randomized clinical trials where the new eye drops were given to half of the participants. Meanwhile, the other half received placebo eye drops.
In neither of the clinical studies, there were any serious side effects reported apart from minor side effects like mild headaches and eye redness. Using eye drops may also cause the user to have temporary problems adjusting their focus.
These drops can be most effective for people who have trouble seeing clearly when doing daily tasks, such as reading on their phones and computers.
